See every side of every news story
Published loading...Updated

Shane Olwill appointed as chief development officer at Asgard Therapeutics - Pharmafile

Summary by pharmafile.com
Asgard Therapeutics has announced the appointment of Shane Olwill as chief development officer (CDO). The biotech company develops in vivo direct cell reprogramming for cancer immunology. Olwill specialises in immunology drug development. In his new position, he will lead Investigational New Drug (IND)-enabling studies and clinical trials planning for Asgard’s AT-108 therapy. This is a […] The post Shane Olwill appointed as chief development off…
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

pharmafile.com broke the news in on Friday, March 28, 2025.
Sources are mostly out of (0)

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.